Back to Journals » OncoTargets and Therapy » Volume 8

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib

Authors Yan Y, Grothey A

Received 13 July 2015

Accepted for publication 9 September 2015

Published 15 October 2015 Volume 2015:8 Pages 2949—2957

DOI https://doi.org/10.2147/OTT.S79145

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Prof. Dr. Haijun Zhang

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati


Yiyi Yan, Axel Grothey

Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA

Abstract: Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibercept. The identification of predictive biomarkers has further improved the survival by accurately selecting patients who are most likely to benefit from these treatments, such as RAS mutation profiling for EGFR antibodies. Regorafenib is a multikinase inhibitor currently used as late line therapy for mCRC. The molecular and genetic markers associated with regorafenib treatment response are yet to be characterized. Here, we review currently available clinical evidence of mCRC molecular profiling, such as RAS, BRAF, and MMR testing, and its role in targeted therapies with special focus on regorafenib treatment.

Keywords: metastatic colon cancer, targeted therapy, molecular profiling, regorafenib
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]